Greenleaf Trust Takes $276,000 Position in Insulet Co. (NASDAQ:PODD)

Greenleaf Trust purchased a new position in shares of Insulet Co. (NASDAQ:PODD) during the fourth quarter, Holdings Channel reports. The firm purchased 1,271 shares of the medical instruments supplier’s stock, valued at approximately $276,000.

Other large investors have also added to or reduced their stakes in the company. Consolidated Portfolio Review Corp increased its holdings in Insulet by 1.6% in the 4th quarter. Consolidated Portfolio Review Corp now owns 3,713 shares of the medical instruments supplier’s stock valued at $806,000 after buying an additional 57 shares during the period. New York Life Investment Management LLC increased its stake in Insulet by 0.8% in the third quarter. New York Life Investment Management LLC now owns 10,035 shares of the medical instruments supplier’s stock valued at $1,600,000 after acquiring an additional 82 shares during the last quarter. Avior Wealth Management LLC increased its stake in Insulet by 3.6% in the fourth quarter. Avior Wealth Management LLC now owns 2,645 shares of the medical instruments supplier’s stock valued at $574,000 after acquiring an additional 91 shares during the last quarter. Allworth Financial LP raised its position in Insulet by 104.5% during the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 92 shares in the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in Insulet by 1.3% during the third quarter. Daiwa Securities Group Inc. now owns 7,316 shares of the medical instruments supplier’s stock worth $1,167,000 after purchasing an additional 93 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms have recently commented on PODD. Barclays lowered their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a report on Monday, February 26th. JPMorgan Chase & Co. boosted their target price on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Piper Sandler reduced their price target on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Finally, Stifel Nicolaus lifted their price target on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a report on Monday, February 5th. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $243.21.

Insulet Stock Performance

NASDAQ PODD opened at $167.25 on Thursday. The company has a market capitalization of $11.71 billion, a price-to-earnings ratio of 57.47, a PEG ratio of 3.01 and a beta of 0.98. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $335.91. The stock has a fifty day simple moving average of $172.53 and a 200 day simple moving average of $179.35.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.73. The company had revenue of $509.80 million during the quarter, compared to analysts’ expectations of $461.26 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The business’s quarterly revenue was up 37.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.55 earnings per share. Sell-side analysts expect that Insulet Co. will post 3.08 EPS for the current year.

Insider Buying and Selling at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares of the company’s stock, valued at approximately $418,215.64. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.90% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.